Reported Earlier, Actuate Therapeutics Prices $22.4M Initial Public Offering Of 2.8M Common Shares At $8/Share
Portfolio Pulse from Benzinga Newsdesk
Actuate Therapeutics has priced its initial public offering (IPO) at $8 per share, raising $22.4 million. The company has also granted underwriters a 30-day option to purchase an additional 420,000 shares. The shares will trade on the Nasdaq Global Market under the symbol 'ACTU' starting August 13, 2024.
August 13, 2024 | 7:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actuate Therapeutics has priced its IPO at $8 per share, raising $22.4 million. The shares will trade on Nasdaq under the symbol 'ACTU' starting August 13, 2024.
The successful pricing of the IPO and the commencement of trading on Nasdaq are positive indicators for Actuate Therapeutics. The raised capital will support the company's growth and operations, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100